Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $22000.0.

  • Guided Therapeutics' Other Operating Expenses fell 7105.26% to $22000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $215000.0, marking a year-over-year decrease of 2402.83%. This contributed to the annual value of $287000.0 for FY2024, which is 708.96% up from last year.
  • Guided Therapeutics' Other Operating Expenses amounted to $22000.0 in Q3 2025, which was down 7105.26% from $51000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Other Operating Expenses registered a high of $76000.0 during Q3 2024, and its lowest value of -$1000.0 during Q2 2022.
  • For the 5-year period, Guided Therapeutics' Other Operating Expenses averaged around $51684.2, with its median value being $52000.0 (2022).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 10370.37% in 2022, then soared by 620000.0% in 2023.
  • Quarter analysis of 5 years shows Guided Therapeutics' Other Operating Expenses stood at $34000.0 in 2021, then skyrocketed by 52.94% to $52000.0 in 2022, then increased by 25.0% to $65000.0 in 2023, then grew by 6.15% to $69000.0 in 2024, then crashed by 68.12% to $22000.0 in 2025.
  • Its last three reported values are $22000.0 in Q3 2025, $51000.0 for Q2 2025, and $73000.0 during Q1 2025.